|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yap TA, Smith AD, Ferraldeschi R,
Al-Lazikani B, Workman P and de Bono JS: Drug discovery in advanced
prostate cancer: Translating biology into therapy. Nat Rev Drug
Discov. 15:699–718. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Keyes M, Crook J, Morton G, Vigneault E,
Usmani N and Morris WJ: Treatment options for localized prostate
cancer. Can Fam Physician. 59:1269–1274. 2013.PubMed/NCBI
|
|
4
|
Dai C, Heemers H and Sharifi N: Androgen
signaling in prostate cancer. Cold Spring Harb Perspect Med.
7(pii): a0304522017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sumanasuriya S and de Bono J: Treatment of
advanced prostate cancer-A review of current therapies and future
promise. Cold Spring Harb Perspect Med. 8(pii): a0306352018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–2512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
De Bono JS, Oudard S, Ozguroglu M, Hansen
S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L,
et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic
castration-resistant prostate cancer progressing after docetaxel
treatment: A randomised open-label trial. Lancet. 376:1147–1154.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seruga B, Ocana A and Tannock IF: Drug
resistance in metastatic castration-resistant prostate cancer. Nat
Rev Clin Oncol. 8:12–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakazawa M, Paller C and Kyprianou N:
Mechanisms of therapeutic resistance in prostate cancer. Curr Oncol
Rep. 19:132017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sridhar SS, Freedland SJ, Gleave ME,
Higano C, Mulders P, Parker C, Sartor O and Saad F:
Castration-resistant prostate cancer: From new pathophysiology to
new treatment. Eur Urol. 65:289–299. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arsov C, Winter C, Rabenalt R and Albers
P: Current second-line treatment options for patients with
castration resistant prostate cancer (CRPC) resistant to docetaxel.
Urol Oncol. 30:762–771. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chandrasekar T, Yang JC, Gao AC and Evans
CP: Mechanisms of resistance in castration-resistant prostate
cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.PubMed/NCBI
|
|
13
|
Gill BS, Kumar S and Navgeet: Triterpenes
in cancer: Significance and their influence. Mol Biol Rep.
43:881–896. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fernandes J, Weinlich R, Castilho RO,
Amarante-Mendes GP and Gattass CR: Pomolic acid may overcome
multidrug resistance mediated by overexpression of anti-apoptotic
Bcl-2 proteins. Cancer Lett. 245:315–320. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lúcio KA, Rocha Gda G, Monção-Ribeiro LC,
Fernandes J, Takiya CM and Gattass CR: Oleanolic acid initiates
apoptosis in non-small cell lung cancer cell lines and reduces
metastasis of a B16F10 melanoma model in vivo. PLoS One.
6:e285962011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yan XJ, Gong LH, Zheng FY, Cheng KJ, Chen
ZS and Shi Z: Triterpenoids as reversal agents for anticancer drug
resistance treatment. Drug Discov Today. 19:482–488. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fernandes J, Castilho RO, da Costa MR,
Wagner-Souza K, Coelho Kaplan MA and Gattass CR: Pentacyclic
triterpenes from Chrysobalanaceae species: Cytotoxicity on
multidrug resistant and sensitive leukemia cell lines. Cancer Lett.
190:165–169. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vasconcelos FC, Gattass CR, Rumjanek VM
and Maia RC: Pomolic acid-induced apoptosis in cells from patients
with chronic myeloid leukemia exhibiting different drug resistance
profile. Invest New Drugs. 25:525–533. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Song Y, Zhang P, Zhu H, Chen L, Xiao
Y and Xing Y: Oleanolic acid inhibits cell survival and
proliferation of prostatecancer cells in vitro and in vivo through
the PI3K/Akt pathway. Tumor Biol. 37:7599–7613. 2016. View Article : Google Scholar
|
|
20
|
Shin J, Lee HJ, Jung DB, Jung JH, Lee HJ,
Lee EO, Lee SG, Shim BS, Choi SH, Ko SG, et al: Suppression of
STAT3 and HIF-1 alpha mediates anti-angiogenic activity of
betulinic acid in hypoxic PC-3 prostate cancer cells. PLoS One.
6:e214922011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shanmugam MK, Manu KA, Ong TH,
Ramachandran L, Surana R, Bist P, Lim LH, Kumar AP, Hui KM and
Sethi G: Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid
leads to suppression of metastasis in transgenic adenocarcinoma of
mouse prostate model. Int J Cancer. 129:1552–1563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
O'Neill AJ, Prencipe M, Dowling C, Fan Y,
Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran
C, et al: Characterisation and manipulation of docetaxel resistant
prostate cancer cell lines. Mol Cancer. 10:1262011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakazawa M, Paller C and Kyprianou N:
Mechanisms of therapeutic resistance in prostate cancer. Curr Oncol
Rep. 19:132017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kojima K, Fujita Y, Nozawa Y, Deguchi T
and Ito M: MiR-34a attenuates paclitaxel-resistance of
hormone-refractory prostate cancer PC3 cells through direct and
indirect mechanisms. Prostate. 70:1501–1512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee BY, Hochgräfe F, Lin HM, Castillo L,
Wu J, Raftery MJ, Martin Shreeve S, Horvath LG and Daly RJ:
Phosphoproteomic profiling identifies focal adhesion kinase as a
mediator of docetaxel resistance in castrate-resistant prostate
cancer. Mol Cancer Ther. 13:190–201. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Karatas OF, Guzel E, Duz MB, Ittmann M and
Ozen M: The role of ATP-binding cassette transporter genes in the
progression of prostate cancer. Prostate. 76:434–444. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu Y, Liu C, Armstrong C, Lou W, Sandher
A and Gao AC: Anti-androgens inhibit ABCB1 efflux and ATPase
activity and reverse docetaxel resistance in advanced prostate
cancer. Clin Cancer Res. 21:4133–4142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lombard AP, Liu C, Armstrong CM, Cucchiara
V, Gu X, Lou W, Evans CP and Gao AC: ABCB1 mediates
cabazitaxel-docetaxel cross-resistance in advanced prostate cancer.
Mol Cancer Ther. 16:2257–2266. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu Y, Liu C, Nadiminty N, Lou W, Tummala
R, Evans CP and Gao AC: Inhibition of ABCB1 expression overcomes
acquired docetaxel resistance in prostate cancer. Mol Cancer Ther.
12:1829–1836. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sánchez C, Mercado A, Contreras HR,
Mendoza P, Cabezas J, Acevedo C, Huidobro C and Castellón EA:
Chemotherapy sensitivity recovery of prostate cancer cells by
functional inhibition and knock down of multidrug resistance
proteins. Prostate. 71:1810–1817. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zalcberg J, Hu XF, Slater A, Parisot J,
El-Osta S, Kantharidis P, Chou ST and Parkin JD: MRP1 not MDR1 gene
expression is the predominant mechanism of acquired multidrug
resistance in two prostate carcinoma cell lines. Prostate Cancer
Prostatic Dis. 3:66–75. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rocha Gda G, Simões M, Oliveira RR, Kaplan
MA and Gattass CR: 3β-acetyl tormentic acid induces apoptosis of
resistant leukemia cells independently of P-gp/ABCB1 activity or
expression. Invest New Drugs. 30:105–113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Meng Y, Lin ZM, Ge N, Zhang DL, Huang J
and Kong F: Ursolic acid induces apoptosis of prostate cancer cells
via the PI3K/Akt/mTOR Pathway. Am J Chin Med. 43:1471–1486. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yoo KH, Park JH, Lee DK, Fu YY, Baek NI
and Chung IS: Pomolic acid induces apoptosis in SK-OV-3 human
ovarian adenocarcinoma cells through the mitochondrial-mediated
intrinsic and death receptor-induced extrinsic pathways. Oncol
Lett. 5:386–390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guimarães LPTP, Rocha GDG, Queiroz RM,
Martins CA, Takiya CM and Gattass CR: Pomolic acid induces
apoptosis and inhibits multidrug resistance protein MRP1 and
migration in glioblastoma cells. Oncol Rep. 38:2525–2534. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tamaki H, Harashima N, Hiraki M, Arichi N,
Nishimura N, Shiina H, Naora K and Harada M: Bcl-2 family
inhibition sensitizes human prostate cancer cells to docetaxel and
promotes unexpected apoptosis under caspase-9 inhibition.
Oncotarget. 5:11399–11412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Park JH, Yoon J and Park B: Pomolic acid
suppresses HIF1α/VEGF-mediated angiogenesis bytargeting p38-MAPK
and mTOR signaling cascades. Phytomedicine. 23:1716–1726. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
McCall P, Bennett L, Ahmad I, Mackenzie
LM, Forbes IW, Leung HY, Sansom OJ, Orange C, Seywright M,
Underwood MA, et al: NFκB signalling is upregulated in a subset of
castrate-resistant prostate cancer patients and correlates with
disease progression. Br J Cancer. 107:1554–1563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Codony-Servat J, Marín-Aguilera M, Visa L,
García-Albéniz X, Pineda E, Fernández PL, Filella X, Gascón P and
Mellado B: Nuclear factor-kappa B and interleukin-6 related
docetaxel resistance in castration-resistant prostate cancer.
Prostate. 73:512–521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang L, Altuwaijri S, Deng F, Chen L, Lal
P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, et al:
NF-kappaB regulates androgen receptor expression and prostate
cancer growth. Am J Pathol. 175:489–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chang L, Graham PH, Hao J, Ni J, Bucci J,
Cozzi PJ, Kearsley JH and Li Y: PI3K/Akt/mTOR pathway inhibitors
enhance radiosensitivity in radioresistant prostate cancer cells
through inducing apoptosis, reducing autophagy, suppressing NHEJ
and HR repair pathways. Cell Death Dis. 5:e14372014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Marín-Aguilera M, Codony-Servat J, Reig Ò,
Lozano JJ, Fernández PL, Pereira MV, Jiménez N, Donovan M, Puig P,
Mengual L, et al: Epithelial-to-mesenchymal transition mediates
docetaxel resistance and high risk of relapse in prostate cancer.
Mol Cancer Ther. 13:1270–1284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Puhr M, Hoefer J, Schäfer G, Erb HH, Oh
SJ, Klocker H, Heidegger I, Neuwirt H and Culig Z:
Epithelial-to-mesenchymal transition leads to docetaxel resistance
in prostate cancer and is mediated by reduced expression of
miR-200c and miR-205. Am J Pathol. 181:2188–2201. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu K, Guo L, Miao L, Bao W, Yang J, Li X,
Xi T and Zhao W: Ursolic acid inhibits epithelial-mesenchymal
transition by suppressing the expression of astrocyte-elevated
gene-1 in human nonsmall cell lung cancer A549 cells. Anticancer
Drugs. 24:494–503. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sohn EJ, Won G, Lee J, Yoon SW, Lee I, Kim
HJ and Kim SH: Blockage of epithelial to mesenchymal transition and
upregulation of let 7b are critically involved in ursolic acid
induced apoptosis in malignant mesothelioma cell. Int J Biol Sci.
12:1279–1288. 2016. View Article : Google Scholar : PubMed/NCBI
|
